<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Queiroz-Telles, F.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Isavuconazole Promising for Cryptococcus spp Infections</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-12</style></pages><abstract><style  face="normal" font="default" size="100%">Isavuconazole treatment in patients with Cryptococcus spp infection resulted in an overall response in 6 of 9 patients, some of whom were refractory to prior therapies. This article presents data from the Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi study [VICAL; NCT00634049], which looked at the treatment in patients with invasive fungal disease.</style></abstract><number><style face="normal" font="default" size="100%">28</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>